2552 Share Price Performance
HK$2.63
-0.10 (-3.66%)
Price HK$2.63
Share Pricen/a
Hua Medicine (Shanghai) Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
2552 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Hua Medicine (Shanghai) Ltd. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 1.11
- 56.87%
- 224.44%
- 25.0%
About 2552
- Founded
- 2011
- Employees
- 328
- CEO
- WebsiteView website
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.
